Author: Liu, Margaret A.
Title: A Comparison of Plasmid DNA and mRNA as Vaccine Technologies Document date: 2019_4_24
ID: 0fx1b7ph_30
Snippet: The potential issues due to the various inflammatory effects of mRNA vaccines upon clinical efficacy and safety are summarized in Table 2 and are discussed below. The possible utility of RNA-induced inflammation for vaccines is demonstrated by the fact that one of the first uses of RNA for vaccines was to include non-coding RNA in human clinical trials as an adjuvant for a rabies vaccine (composed of an inactivated virus) [54] , although this eff.....
Document: The potential issues due to the various inflammatory effects of mRNA vaccines upon clinical efficacy and safety are summarized in Table 2 and are discussed below. The possible utility of RNA-induced inflammation for vaccines is demonstrated by the fact that one of the first uses of RNA for vaccines was to include non-coding RNA in human clinical trials as an adjuvant for a rabies vaccine (composed of an inactivated virus) [54] , although this effort has been replaced by a rabies vaccine that utilizes mRNA that itself encodes the rabies antigen [55] , as is discussed below. The continued evaluation of non-coding RNA as an adjuvant is ongoing in clinical testing for various cancers without the provision of an antigen (see below). Table 2 . Issues to be addressed for clinical efficacy and safety of mRNA related to inflammation.
Search related documents:
Co phrase search for related documents- cancer clinical testing and clinical trial: 1
- clinical efficacy and continue evaluation: 1, 2
- clinical efficacy and human clinical trial: 1, 2, 3, 4, 5
- clinical efficacy and inactivated virus: 1, 2, 3, 4, 5, 6, 7, 8
- clinical efficacy and inflammatory effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- clinical efficacy and mRNA vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
- clinical efficacy and RNA induce: 1
- clinical efficacy and safety clinical efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- clinical testing and inactivated virus: 1, 2, 3, 4, 5, 6, 7, 8, 9
- clinical testing and mRNA vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- clinical testing and potential issue: 1
- clinical testing and safety clinical efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- clinical trial and continue evaluation: 1
- clinical trial and human clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54
- clinical trial and inactivated virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- clinical trial and inflammatory effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- clinical trial and mRNA vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
- clinical trial and safety clinical efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- continue evaluation and human clinical trial: 1
Co phrase search for related documents, hyperlinks ordered by date